Table 6.
Comparative analysis of demographic and epidemiological variables related to hepatitis C virus according to the presence or absence of RASs to direct-acting antiviral agents (n=76)
| Variable | N (%) Presence of RASs | Absence of RASs | P (<0.05) |
|---|---|---|---|
|
| |||
| Age (mean ± SD), years | 54.7±10.6 | 55±9.6 | 0.95 |
| Gender | |||
| Female | 12/30 (40%) | 18/30 (60%) | 0.79 |
| Male | 17/46 (37%) | 29/46 (63%) | |
| Genotype 1a | 18/42 (42.9%) | 24/42 (57.1%) | 0.35 |
| Genotype 1b | 11/34 (32.4%) | 23/34 (67.6%) | |
| CKD patients on HD | 13/37 (35.1%) | 24/37 (64.9%) | 0.60 |
| RTx recipients | 23/39 (59%) | 16/39 (41%) | |
| Duration of HD (mean ± SD), years | 5.8±4.3 | 7.8±6.6 | 0.51 |
| Time after renal transplant (mean ± SD), years | 14.6±7.9 | 8.4±5.8 | 0.01 |
| Treatment-naïve | |||
| Treatment experienced | 19/40 (47%) | 21/40 (53%) | 0.07 |
| (Peg-IFN+RBV) | 10/36 (27.8%) | 26/36 (72.2%) | |
Abbreviations: RASs, resistance-associated substitutions; CKD, chronic kidney disease; HD, hemodialysis; RTx, renal transplant; Peg-IFN, pegylated interferon; RBV, ribavirin.